Recurrence after stopping anticoagulants in women with combined oral contraceptive-associated venous thromboembolism: A systematic review and meta-analysis.
contraceptive agents
oestrogens
oral contraceptive
recurrence
venous thromboembolism
venous thrombosis
women
Journal
British journal of haematology
ISSN: 1365-2141
Titre abrégé: Br J Haematol
Pays: England
ID NLM: 0372544
Informations de publication
Date de publication:
10 2022
10 2022
Historique:
revised:
08
06
2022
received:
11
05
2022
accepted:
13
06
2022
pubmed:
26
7
2022
medline:
28
9
2022
entrez:
25
7
2022
Statut:
ppublish
Résumé
The risk of recurrence after discontinuation of anticoagulation for a combined oral contraceptive (COC)-associated venous thromboembolism (VTE) is unclear. Therefore, we conducted a systematic review and meta-analysis to estimate the incidence of recurrent VTE among women with COC-associated VTE, unprovoked VTE and to compare the incidence of recurrent VTE between the two groups. The Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, Embase Classic +Embase and Medline ALL to July 2020 and citations from included studies were searched. Randomized controlled trials, prospective cohort studies and meta-analyses of these study types were selected. The analysis was conducted by random-effects model. Nineteen studies were identified including 1537 women [5828 person-years (PY)] with COC-associated VTE and 1974 women (7798 PY) with unprovoked VTE. Studies were at low risk of bias. The incidence rate of VTE recurrence was 1.22/100 PY [95% confidence interval (CI) 0.92-1.62, I
Substances chimiques
Anticoagulants
0
Contraceptives, Oral, Combined
0
Types de publication
Journal Article
Meta-Analysis
Systematic Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
130-142Informations de copyright
© 2022 British Society for Haematology and John Wiley & Sons Ltd.
Références
Kearon C, Ageno W, Cannegieter SC, Cosmi B, Geersing GJ, Kyrle PA, et al. Categorization of patients as having provoked or unprovoked venous thromboembolism: guidance from the SSC of ISTH. J Thromb Haemost. 2016;14(7):1480-3.
Stevens SM, Woller SC, Kreuziger LB, Bounameaux H, Doerschug K, Geersing GJ, et al. Antithrombotic therapy for VTE disease: second update of the CHEST guideline and expert panel report - executive summary. Chest. 2021;160:e545-608.
Eischer L, Eichinger S, Kyrle PA. The risk of recurrence in women with venous thromboembolism while using estrogens: a prospective cohort study. J Thromb Haemost. 2014;12(5):635-40.
Kearon C, Parpia S, Spencer FA, Schulman S, Stevens SM, Shah V, et al. Long-term risk of recurrence in patients with a first unprovoked venous thromboembolism managed according to D-dimer results; a cohort study. J Thromb Haemost. 2019;17:1144-52.
Douketis J, Tosetto A, Marcucci M, Baglin T, Cosmi B, Cushman M, et al. Risk of recurrence after venous thromboembolism in men and women: patient level meta-analysis. BMJ. 2011;342:d813.
Aziz D, Skeith L, Rodger MA, Sabri E, Righini M, Kovacs MJ, et al. Long-term risk of recurrent venous thromboembolism after a first contraceptive-related event: data from REVERSE cohort study. J Thromb Haemost. 2021;19:1526-32.
Le Moigne E, Delluc A, Tromeur C, Nowak E, Mottier D, Lacut K, et al. Risk of recurrent venous thromboembolism among young women after a first event while exposed to combined oral contraception versus not exposed to: a cohort study. Thromb Res. 2013;132(1):51-5.
Cushman M, Glynn RJ, Goldhaber SZ, Moll S, Bauer KA, Deitcher S, et al. Hormonal factors and risk of recurrent venous thrombosis: the prevention of recurrent venous thromboembolism trial. J Thromb Haemost. 2006;4(10):2199-203.
Skeith L, Le Gal G, Rodger MA. Oral contraceptives and hormone replacement therapy: how strong a risk factor for venous thromboembolism? Thromb Res. 2021;202:134-8.
Brooke BS, Schwartz TA, Pawlik TM. MOOSE reporting guidelines for meta-analyses of observational studies. JAMA Surg. 2021;156(8):787-8.
Rayyan QCRI. August 8, 2019; Available from: https://rayyan.qcri.org/welcome.
GA Wells, B Shea, D O'Connell, J Peterson, V Welch, M Losos, P Tugwell. The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. 2011; Available from: www.ohri.ca/programs/clinical_epidemiology/oxford.htm.
Tait R, GDO L, MD MC, AD MM, Robertson L, King L. Predicting risk of recurrent venous thrombosis using a 5-point scoring system including fibrin D-dimer. J Thromb Haemost. 2007;5(suppl 2):O-M-060S.
Baglin T, Palmer CR, Luddington R, Baglin C. Unprovoked recurrent venous thrombosis: prediction by D-dimer and clinical risk factors. J Thromb Haemost. 2008;6(4):577-82.
Cosmi B, Legnani C, Tosetto A, Pengo V, Ghirarduzzi A, Testa S, et al. Sex, age and normal post-anticoagulation D-dimer as risk factors for recurrence after idiopathic venous thromboembolism in the Prolong study extension. J Thromb Haemost. 2010;8(9):1933-42.
Palareti G, Cosmi B, Legnani C, Antonucci E, de Micheli V, Ghirarduzzi A, et al. D-dimer to guide the duration of anticoagulation in patients with venous thromboembolism: a management study. Blood. 2014;124(2):196-203.
Rodger MA, le Gal G, Anderson DR, Schmidt J, Pernod G, Kahn SR, et al. Validating the HERDOO2 rule to guide treatment duration for women with unprovoked venous thrombosis: multinational prospective cohort management study. BMJ. 2017;356:j1065.
Schulman S, Lindmarker P, Holmström M, Lärfars G, Carlsson A, Nicol P, et al. Post-thrombotic syndrome, recurrence, and death 10 years after the first episode of venous thromboembolism treated with warfarin for 6 weeks or 6 months. J Thromb Haemost. 2006;4(4):734-42.
Christiansen SC, Cannegieter SC, Koster T, Vandenbroucke JP, Rosendaal FR. Thrombophilia, clinical factors, and recurrent venous thrombotic events. JAMA. 2005;293(19):2352-61.
Poli D, Antonucci E, Ciuti G, Abbate R, Prisco D. Combination of D-dimer, F1+2 and residual vein obstruction as predictors of VTE recurrence in patients with first VTE episode after OAT withdrawal. J Thromb Haemost. 2008;6(4):708-10.
Rodger MA, Scarvelis D, Kahn SR, Wells PS, Anderson DA, Chagnon I, et al. Long-term risk of venous thrombosis after stopping anticoagulants for a first unprovoked event: a multi-national cohort. Thromb Res. 2016;143:152-8.
Palareti G, Legnani C, Cosmi B, Guazzaloca G, Pancani C, Coccheri S. Risk of venous thromboembolism recurrence: high negative predictive value of D-dimer performed after oral anticoagulation is stopped. Thromb Haemost. 2002;87(1):7-12.
Shrivastava S, Ridker PM, Glynn RJ, Goldhaber SZ, Moll S, Bounameaux H, et al. D-dimer, factor VIII coagulant activity, low-intensity warfarin and the risk of recurrent venous thromboembolism. J Thromb Haemost. 2006;4(6):1208-14.
Khan F, Tritschler T, Kimpton M, Wells PS, Kearon C, Weitz JI, et al. Long-term risk for major bleeding during extended Oral anticoagulant therapy for first unprovoked venous thromboembolism : a systematic review and meta-analysis. Ann Intern Med. 2021;174(10):1420-9.
HMG W, Knijp J, van Es N, Coppens M, Moll S, Klok FA, et al. Risk of recurrence in women with venous thromboembolism related to oestrogen-containing contraceptives: systematic review and meta-analysis. J Thromb Haemost. 2022;20:1158-65.
Tosetto A, Iorio A, Marcucci M, Baglin T, Cushman M, Eichinger S, et al. Predicting disease recurrence in patients with previous unprovoked venous thromboembolism: a proposed prediction score (DASH). J Thromb Haemost. 2012;10(6):1019-25.
Tosetto A, Testa S, Martinelli I, Poli D, Cosmi B, Lodigiani C, et al. External validation of the DASH prediction rule: a retrospective cohort study. J Thromb Haemost. 2017;15(10):1963-70.
Olie V, Zhu T, Martinez I, Scarabin PY, Emmerich J. Sex-specific risk factors for recurrent venous thromboembolism. Thromb Res. 2012;130(1):16-20.
Jones J, Mosher W, Daniels K. Current contraceptive use in the United States, 2006-2010, and changes in patterns of use since 1995. National health statistics reports; no 60. Hyattsville, MD: National Center for Health Statistics; 2012.
Nagler M, ten Cate H, Prins MH, ten Cate-Hoek AJ. Risk factors for recurrence in deep vein thrombosis patients following a tailored anticoagulant treatment incorporating residual vein obstruction. Res Pract Thromb Haemost. 2018;2(2):299-309.
Tchaikovski SN, Rosing J. Mechanisms of estrogen-induced venous thromboembolism. Thromb Res. 2010;126(1):5-11.
Lidegaard O, Lokkegaard E, Svendsen AL, Agger C. Hormonal contraception and risk of venous thromboembolism: national follow-up study. BMJ. 2009;339:b2890.
de Bastos M, Stegeman BH, Rosendaal FR, van Hylckama Vlieg A, Helmerhorst FM, Stijnen T, et al. Combined oral contraceptives: venous thrombosis. Cochrane Database Syst Rev. 2014;3:CD010813.
van Hylckama Vlieg A, Helmerhorst FM, Vandenbroucke JP, Doggen CJM, Rosendaal FR. The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study. BMJ. 2009;339:b2921.
Gialeraki A, Valsami S, Pittaras T, Panayiotakopoulos G, Politou M. Oral contraceptives and HRT risk of thrombosis. Clin Appl Thromb Hemost. 2018;24(2):217-25.
Heit JA, Mohr DN, Silverstein MD, Petterson TM, O'Fallon WM, Melton LJ. Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. Arch Intern Med. 2000;160(6):761-8.
Kearon C, Iorio A, Palareti G, Subcommittee on Control of Anticoagulation of the SSC of the ISTH. Risk of recurrent venous thromboembolism after stopping treatment in cohort studies: recommendation for acceptable rates and standardized reporting. J Thromb Haemost. 2010;8(10):2313-5.
Miranda B, Ferro J´M, Canhão P´, Stam J, Bousser MG, Barinagarrementeria F, et al. Venous thromboembolic events after cerebral vein thrombosis. Stroke. 2010;41(9):1901-6.
Zabczyk M, Plens K, Wojtowicz W, Undas A. Prothrombotic fibrin clot phenotype is associated with recurrent pulmonary embolism after discontinuation of anticoagulant therapy. Arterioscler Thromb Vasc Biol. 2017;37(2):365-73.
Pires GS, Ribeiro DD, Oliveira JAQ, Freitas LC, Vaez R, Annichino-Bizzacchi JM, et al. Risk factors associated with recurrent venous thromboembolism after a first cerebral venous thrombosis event: a cohort study. Thromb Res. 2019;178:85-90.